Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
17.12 USD -0.03 ( 0.17%)
Last update at 2026-11-20T20:51:00Z
VOLUME
7501
Market Cap
26644.18M
P/E
13.89

Momentum Score

…

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
17.12
Low
17.35
High
52 Week Price Range
10.08
Low
16.77
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Astellas Pharma Inc is a Japan-based global pharmaceutical company focused on discovering, developing and commercializing therapies primarily in oncology, urology, transplantation and other specialty areas. Its long-term growth may be driven by new oncology indications and launches, pipeline advances including regenerative and gene therapies, and revenues from established products across developed and emerging markets, which could support steady cash flow and scale.

Primary investment risks include patent expirations on key products, regulatory and clinical trial setbacks, competitive pressures and pricing or reimbursement headwinds that could impair revenues.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
17.15
Dividend Yield
3.33%
Revenue TTM
2274365.01M
Revenue Per Share
1269.54
Gross Profit TTM
1838066.04M
Debt / Equity
0.13
ROE
21.30%
Net Debt
-35807.63M
ROCE
18.87%
Diluted EPS TTM
1.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax 399298.15M 31237.00M 24969.00M 132361.00M 156886.00M
Minority interest -40.00M - - - -
Net income 309116.85M 50747.00M 17045.00M 98714.00M 124086.00M
Selling general administrative 860312.00M 843032.00M 740110.00M 630272.00M 548840.00M
Gross profit 1691018.18M 1563117.00M 1311187.00M 1230266.00M 1043154.00M
Reconciled depreciation 194594.00M 199132.00M 157840.00M 105738.00M 79684.00M
Ebit 445009.08M 48914.00M 36974.00M 140928.00M 137601.00M
Ebitda 651338.63M 248046.00M 194814.00M 246666.00M 217285.00M
Depreciation and amortization 206329.55M 199132.00M 157840.00M 105738.00M 79684.00M
Operating income 445009.08M 41039.00M 25518.00M 133029.00M 155686.00M
Other operating expenses 1823249.18M 1871284.00M 1578154.00M 1387062.00M 1165200.00M
Interest expense 14920.65M 17677.00M 12005.00M 8779.00M 4949.00M
Tax provision 85013.00M -19510.00M 7924.00M 33647.00M 32800.00M
Interest income 8026.00M 7874.00M 11455.00M 8110.00M 6149.00M
Net interest income -6046.00M -9803.00M -550.00M -669.00M 1200.00M
Income tax expense 90139.95M -19510.00M 7924.00M 33647.00M 32800.00M
Total revenue 2268258.26M 1912323.00M 1603672.00M 1518619.00M 1296163.00M
Total operating expenses 1246009.10M 1522078.00M 1285669.00M 1098709.00M 912191.00M
Cost of revenue 577240.07M 349206.00M 292485.00M 288353.00M 253009.00M
Total other income expense net -45710.93M -9802.00M -549.00M -99291.00M -61259.00M
Net income from continuing ops 291574.00M 50747.00M 17045.00M 98714.00M 124086.00M
Net income applicable to common shares - - - - 124086.00M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 3582512.86M 3339544.00M 3569603.00M 2456518.00M 2332395.00M
Intangible assets 1001255.86M 1123714.00M 1453824.00M 562496.00M 623431.00M
Other current assets 47747.19M 53250.00M 46536.00M 32428.00M 28998.00M
Total liab 1743688.01M 1826289.00M 1973615.00M 948564.00M 872087.00M
Total stockholder equity 1838824.85M 1513255.00M 1595988.00M 1507954.00M 1460308.00M
Other current liab 776048.32M 572688.00M 589739.00M 585798.00M 556672.00M
Common stock 103447.73M 103001.00M 103001.00M 103001.00M 103001.00M
Capital stock 103001.00M 103001.00M 103001.00M 103001.00M 103001.00M
Retained earnings 906751.75M 740939.00M 809400.00M 908158.00M 944261.00M
Other liab - - - 106852.00M 128986.00M
Good will 443088.45M 415207.00M 418694.00M 328411.00M 303030.00M
Other assets - - - 84170.00M 72330.00M
Cash 282826.37M 188372.00M 335687.00M 376840.00M 315986.00M
Total current liabilities 1223685.41M 1061610.00M 1285725.00M 726034.00M 687411.00M
Current deferred revenue - - 38515.00M - -
Net debt -35807.63M 643054.00M 584329.00M -376840.00M -315986.00M
Short term debt 247018.73M 266533.00M 472278.00M - -
Short long term debt 245952.00M 266533.00M 472278.00M - -
Short long term debt total 247018.73M 831426.00M 920016.00M - -
Other stockholder equity 152717.50M 669315.00M 683587.00M -1011159.00M -1047262.00M
Property plant equipment - - - 286459.00M 269044.00M
Total current assets 1428090.12M 1201349.00M 1194730.00M 1049954.00M 923354.00M
Net tangible assets - - - - 533847.00M
Short term investments 9572.00M 29941.00M 28784.00M 19784.00M 21297.00M
Net receivables 765066.89M 632525.00M 534985.00M 446516.00M 404001.00M
Long term debt 320000.00M 564893.00M 447738.00M - -
Inventory 332449.66M 297261.00M 248738.00M 174386.00M 153072.00M
Accounts payable 200618.36M 187840.00M 185193.00M 140236.00M 130739.00M
Accumulated other comprehensive income 675907.87M - 533301.00M - -
Non currrent assets other 43595.26M 1.00M 45595.00M 1.00M -1.00M
Non current assets total 2154422.74M 2138195.00M 2374873.00M 1406564.00M 1409041.00M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments 0.00M -89419.00M -845802.00M -84500.00M -62413.00M
Change to liabilities - - - 0.00M -10101.00M
Total cashflows from investing activities -77174.51M -89419.00M -845802.00M - -62413.00M
Net borrowings -267418.00M -88522.00M 771233.00M -15000.00M -60000.00M
Total cash from financing activities -429190.35M -261367.00M 614060.00M -195623.00M -216298.00M
Change to operating activities - - - - -16639.00M
Net income 309116.85M 31237.00M 17045.00M 132361.00M 156886.00M
Change in cash 81555.28M -147315.00M -41153.00M 60854.00M -10142.00M
Begin period cash flow 201271.09M 335687.00M 376840.00M 315986.00M 326128.00M
End period cash flow 282826.37M 188372.00M 335687.00M 376840.00M 315986.00M
Total cash from operating activities 600400.38M 194512.00M 172475.00M 327767.00M 257444.00M
Depreciation 1291.34M 199132.00M 157840.00M 105738.00M 79684.00M
Other cashflows from investing activities 12575.25M -65336.00M -22772.00M - -10017.00M
Dividends paid 144306.84M 128993.00M 116653.00M -100355.00M -85236.00M
Change to inventory -17196.07M -50225.00M -60036.00M -7086.00M 24058.00M
Change to account receivables -67641.28M -104735.00M -55948.00M -4849.00M -8001.00M
Sale purchase of stock -774.02M -6960.00M -10735.00M -60556.00M -50717.00M
Other cashflows from financing activities -197383.73M -36892.00M -29785.00M -3217.00M -2530.00M
Change to netincome - - - 15688.00M 31557.00M
Capital expenditures 61204.15M 57330.00M 82497.00M 88541.00M 76448.00M
Change in working capital 29036.53M -166369.00M -86518.00M -24209.00M 5956.00M
Other non cash items 262247.00M 130512.00M 84108.00M 113877.00M 14918.00M
Free cash flow 539196.23M 137182.00M 89978.00M 239226.00M 180996.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ALPMY
Astellas Pharma Inc
-0.03
0.17%
17.12 13.89 12.82 0.01 2.09 2.08 7.59
LLY
Eli Lilly and Company
-1.20
0.09%
1347.11 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson
5.53
2.07%
272.67 30.96 20.79 6.58 7.55 6.84 19.73
ABBV
AbbVie Inc
-0.20
0.07%
286.20 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation
-
-%
480.00 24.16 16.53 5.71 8.88 4.94 14.76

Profile*

Astellas Pharma Inc

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

2-5-1, Nihonbashi-Honcho, Chuo, Japan, 103-8411

81 3 3244 3000

14099

Name Title Year Born
Mr. Kenji Yasukawa Ph.D. Pres, CEO & Chairman 1960
Mr. Naoki Okamura BSc Exec. VP, Chief Strategy Officer & Representative Director NA
Minoru Kikuoka CFO & Sr. Managing Exec. Officer NA
Nobue Yasuda Gen. Mang. of Fin. & Accounting Department NA
Mr. Yoshitsugu Shitaka Ph.D. Chief Scientific Officer & Sr. Managing Exec. Officer NA
Ms. Catherine B. Levitt Gen. Counsel NA
Mr. Katsuyoshi Sugita Chief People Officer and Chief Ethics & Compliance Officer NA
Mr. Stig Ogata VP of Corp. Communications NA
Ms. Collette Taylor Sr. VP of HR 1963
Chihiro Yokota Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…